James C. Meek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
James C. Meek has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alshaimaa Hazaa
Department of Biomedical Engineering, University of Arkansas, Fayetteville, AR 72701, USA
1 shared publication Daniel Borja-Cacho
Department of Surgery, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
1 shared publication- Drew T. Castleberry
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR
1 shared publication - Emmanouil Giorgakis
Division of Abdominal Transplantation, Department of Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA
1 shared publication - Fares A. Mashal
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR
1 shared publication - Felicia Allard
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Porto Sinusoidal Vascular Disorder Manifesting as Diffuse Arterio-Portal Fistulae and Portal Hypertension After Donation-After-Circulatory-Death Liver Transplantation
Ischemic cholangiopathy (ICP) is a rare complication of orthotopic liver transplantation (LT), with an increased incidence in donation-after-circulatory-death (DCD) recipients, particularly without machine perfusion. As DCD utilization increases, challenges arise. We report a rare case of DCD-LT resulting in ICP, complicated by diffuse intrahepatic arterio-portal fistulae (APF) leading to portal hypertension and refractory ascites without any other cause. The candidate was relisted for LT, and the explant revealed diffuse intrahepatic APF and porto-sinusoidal vascular disorder (PSVD) without cirrhosis. To the best of our knowledge, no similar reports exist of LT recipients developing PSVD or diffuse APF, and their concurrence with ICP after DCD-LT raises concern for an association. This case report highlights the importance of considering diffuse APF and PSVD in LT recipients with ICP who develop features of portal hypertension without a clear cirrhotic etiology.
- 30 June 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Open AccessPorto Sinusoidal Vascular Disorder Manifesting as Diffuse Arterio-Portal Fistulae and Portal Hypertension After Donation-After-Circulatory-Death Liver Transplantation
Ischemic cholangiopathy (ICP) is a rare complication of orthotopic liver transplantation (LT), with an increased incidence in donation-after-circulatory-death (DCD) recipients, particularly without machine perfusion. As DCD utilization increases, challenges arise. We report a rare case of DCD-LT resulting in ICP, complicated by diffuse intrahepatic arterio-portal fistulae (APF) leading to portal hypertension and refractory ascites without any other cause. The candidate was relisted for LT, and the explant revealed diffuse intrahepatic APF and porto-sinusoidal vascular disorder (PSVD) without cirrhosis. To the best of our knowledge, no similar reports exist of LT recipients developing PSVD or diffuse APF, and their concurrence with ICP after DCD-LT raises concern for an association. This case report highlights the importance of considering diffuse APF and PSVD in LT recipients with ICP who develop features of portal hypertension without a clear cirrhotic etiology.
- Open Access
- 3 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1870
In Vitro Blood Clot Formation and Dissolution for Testing New Stroke-Treatment Devices
Strokes are among the leading causes of death worldwide. Ischemic stroke, due to plaque or other buildup blocking blood flow to the brain, is the most common type. Although ischemic stroke is treatable, current methods have severe shortcomings with high mortality rates. Clot retrieval devices, for example, can result in physically damaged vessels and death. This study aims to create blood clots that are representative of those found in vivo and demonstrate a new method of removing them. Static blood clots were formed using a 9:1 ratio of whole sheep blood and 2.45% calcium chloride solution. This mixture was heated in a water bath at 37 °C for approximately one hour until solidified. Following clot solidification, human plasmin was introduced by various methods, including soaking, injection, and membrane perfusion, and the resulting dissolution percentages were determined. Different clot types, representative of the wide range found physiologically, were also manufactured and their dissolution characteristics evaluated. A method to reproducibly create blood clots, characteristic of those found in vivo, is essential for the production of stroke retrieval devices that can efficiently and effectively remove clots from patients with low mortality rates and little/no damage to the surrounding vessels.
- 3 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1870
Open AccessIn Vitro Blood Clot Formation and Dissolution for Testing New Stroke-Treatment Devices
Strokes are among the leading causes of death worldwide. Ischemic stroke, due to plaque or other buildup blocking blood flow to the brain, is the most common type. Although ischemic stroke is treatable, current methods have severe shortcomings with high mortality rates. Clot retrieval devices, for example, can result in physically damaged vessels and death. This study aims to create blood clots that are representative of those found in vivo and demonstrate a new method of removing them. Static blood clots were formed using a 9:1 ratio of whole sheep blood and 2.45% calcium chloride solution. This mixture was heated in a water bath at 37 °C for approximately one hour until solidified. Following clot solidification, human plasmin was introduced by various methods, including soaking, injection, and membrane perfusion, and the resulting dissolution percentages were determined. Different clot types, representative of the wide range found physiologically, were also manufactured and their dissolution characteristics evaluated. A method to reproducibly create blood clots, characteristic of those found in vivo, is essential for the production of stroke retrieval devices that can efficiently and effectively remove clots from patients with low mortality rates and little/no damage to the surrounding vessels.
- Open Access
- 28 December 2017
- Published by Elsevier in Radiology Case Reports
- Vol. 13 (2) , 522-526
Use of a mechanical thrombectomy device to treat early hepatic artery thrombosis after orthotopic liver transplant
- 28 December 2017
- Published by Elsevier in Radiology Case Reports
- Vol. 13 (2) , 522-526
Open AccessUse of a mechanical thrombectomy device to treat early hepatic artery thrombosis after orthotopic liver transplant